Skip to main content

Angiex exploits fundamental mechanisms of biology to gain revolutionary power over cancer. Angiex’s founders are world-class scientists and experts in angiogenesis who discovered a nuclear internalization biology that is operative in the tumor environment and enables a new class of drugs: Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). Angiex’s Nuclear Delivery Platform™ delivers chemotherapeutic payloads to the nucleus of tumor cells and the endothelial cells of tumor blood vessels, offering the potential to create drugs for solid cancers with exceptional efficacy and therapeutic margin.

Angiex’s lead ND-ADC, AGX101, enters the clinic in 2022, and a pipeline of additional ND-ADCs is in discovery-stage development. Angiex founders discovered VEGF-A, have been recognized as the world’s leading experts in tumor blood vessel biology, developed new methods for per cell mRNA quantification, founded four companies, wrote a best-selling diet book, and won second prize for best salsa recipe at LabCentral. Angiex is eager to team up with creative talents to end the scourge of cancer.

Leadership Team

Marty J. Duvall

Chief Executive Officer

Marty J. Duvall is an experienced oncology leader with 30+ years of pharmaceutical drug development experience. Prior to Angiex, he was CEO of Tocagen and Oncopeptides; Chief Commercial Officer at ARIAD Pharmaceuticals (now Takeda); Oncology Therapeutic Franchise Head at Merck; Head of Commercial at MGI Pharma (now Eisai) and Abraxis Bioscience (now Celgene); Global Head of Taxotere Medical and Marketing at Aventis (now Sanofi).

Iain Dukes, D.Phil.

Executive Chairman

Iain Dukes is executive chairman of Angiex, and venture partner at Orbimed Advisors. He has served as CEO or chairman of numerous biotherapeutics companies including Theseus Pharmaceuticals, Iovance, KaNDY Therapeutics, Viriom. Before joining Orbimed, Iain was SVP BD & Licensing at Merck; before Merck Iain was VP External R&D at Amgen.

Paul Jaminet, Ph.D.

Founder, President and COO

Paul Jaminet, Ph.D., is founder, president, and COO at Angiex. Paul began his career as an Astrophysicist at the Harvard-Smithsonian Center for Astrophysics before becoming a software entrepreneur during the Internet boom of the 1990s. Paul has 20 years of experience as an entrepreneur-executive in health and technology businesses. Immediately prior to Angiex he founded the Perfect Health Retreat (2013-present) and PerfectHealthDiet.com (2010-present), and wrote the book Perfect Health Diet (Scribner, 2012). He holds a Ph.D. in physics from the University of California at Berkeley and B.S. degrees in physics and philosophy from the Massachusetts Institute of Technology.

Shou-Ching Jaminet, Ph.D.

Founder, VP of Discovery Science

Shou-Ching Jaminet, Ph.D., is founder and VP of Discovery Science at Angiex. Shou-Ching is a molecular and vascular biologist, a leading expert on gene expression profiling and TM4SF1 biology, and discoverer of TM4SF1’s roles in endothelial cell biology. Before coming to Angiex, she was Director of the Laboratory of Multi-Gene Transcriptional Profiling at Beth Israel Deaconess Medical Center, and member of faculty at Harvard Medical School. She is co-author of Perfect Health Diet (Scribner, 2012).

Dr. Harold (Hal) Dvorak, M.D.

Founder, Chair of Scientific Advisory Board

Harold (Hal) Dvorak, M.D., is founder and chair of the scientific advisory board at Angiex, and Mallinckrodt Distinguished Professor of Pathology Emeritus at Harvard Medical School. Hal is best known as the discoverer of VEGF-A and is a leading expert on tumor vessel structures. He was Chief of the Department of Pathology at Beth Israel Deaconess Medical Center from 1979 to 2005, Director of the Center for Vascular Biology Research at BIDMC from 2003 to 2010, and is currently Director at the BIDMC Cancer Center. He is a recipient of the Gairdner International Award (2014) and numerous other prizes and honors.

Board of Directors

Iain Dukes

Marty Duvall

Paul Jaminet

Errik Anderson

Jason Camm

Thiel Capital

Fabian Hansen

Presight Capital

Karen Chu

Fontus Capital